Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX
Vertex Pharmaceuticals Incorporated stock price today
$390.5
-18.25
-4.47%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Vertex Pharmaceuticals Incorporated stock price monthly change
-16.36%
month
Vertex Pharmaceuticals Incorporated stock price quarterly change
-16.36%
quarter
Vertex Pharmaceuticals Incorporated stock price yearly change
+0.17%
year
Vertex Pharmaceuticals Incorporated key metrics
Market Cap | 102.10B |
Enterprise value | 73.75B |
P/E | 25.38 |
EV/Sales | 8.25 |
EV/EBITDA | 16.62 |
Price/Sales | 9.34 |
Price/Book | 5.99 |
PEG ratio | 0.59 |
EPS | 15.57 |
Revenue | 10.18B |
EBITDA | 4.73B |
Income | 4.01B |
Revenue Q/Q | 13.15% |
Revenue Y/Y | 10.57% |
Profit margin | 37.2% |
Oper. margin | 48.23% |
Gross margin | 87.9% |
EBIT margin | 48.23% |
EBITDA margin | 46.48% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVertex Pharmaceuticals Incorporated stock price history
Vertex Pharmaceuticals Incorporated stock forecast
Vertex Pharmaceuticals Incorporated financial statements
Average Price Target
$493.78
Potential upside: 26.44%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2.49B | 915.7M | 36.73% |
|---|---|---|---|
| Sep 2023 | 2.48B | 1.03B | 41.69% |
| Dec 2023 | 2.51B | 968.8M | 38.48% |
| Mar 2024 | 2.68B | 1.09B | 40.92% |
| 2023-08-01 | 3.88 | 3.25 |
|---|
| Jun 2023 | 20349200000 | 4.87B | 23.98% |
|---|---|---|---|
| Sep 2023 | 21726200000 | 5.21B | 24% |
| Dec 2023 | 22730200000 | 5.14B | 22.66% |
| Mar 2024 | 23917400000 | 5.37B | 22.46% |
| Jun 2023 | 1.13B | -303.9M | 17.3M |
|---|---|---|---|
| Sep 2023 | 1.26B | -117.7M | -165M |
| Dec 2023 | 234.6M | -886.5M | -119.8M |
| Mar 2024 | 1.30B | -2.13B | -357.5M |
Vertex Pharmaceuticals Incorporated alternative data
Vertex Pharmaceuticals Incorporated Social Media Accounts
What are followers?
+1.98%
month
| May 2025 | 11646 |
|---|---|
| Jul 2025 | 12490 |
| Aug 2025 | 12737 |
Areas of Focus
| 13 Aug 2023 | 30 |
|---|---|
| 20 Aug 2023 | 33 |
| 27 Aug 2023 | 36 |
| 3 Sep 2023 | 36 |
| 10 Sep 2023 | 36 |
| 17 Sep 2023 | 34 |
| 24 Sep 2023 | 36 |
| 1 Oct 2023 | 34 |
| 8 Oct 2023 | 34 |
| 15 Oct 2023 | 33 |
| 22 Oct 2023 | 30 |
| 29 Oct 2023 | 34 |
| 5 Nov 2023 | 38 |
| 12 Nov 2023 | 33 |
| 19 Nov 2023 | 36 |
| 26 Nov 2023 | 34 |
| 3 Dec 2023 | 30 |
| 10 Dec 2023 | 27 |
| 17 Dec 2023 | 26 |
| 24 Dec 2023 | 28 |
Vertex Products
| 29 Jan 2023 | 13 | 5 | 8 | 0 |
|---|---|---|---|---|
| 5 Feb 2023 | 7 | 3 | 6 | 0 |
| 12 Feb 2023 | 4 | 0 | 9 | 3 |
| 19 Feb 2023 | 5 | 4 | 9 | 3 |
| 26 Feb 2023 | 5 | 2 | 9 | 4 |
| 5 Mar 2023 | 7 | 3 | 8 | 0 |
| 12 Mar 2023 | 9 | 9 | 6 | 0 |
| 19 Mar 2023 | 4 | 5 | 7 | 0 |
| 26 Mar 2023 | 7 | 0 | 9 | 0 |
| 2 Apr 2023 | 6 | 2 | 5 | 0 |
| 9 Apr 2023 | 9 | 2 | 3 | 2 |
| 16 Apr 2023 | 9 | 3 | 9 | 0 |
| 23 Apr 2023 | 8 | 0 | 6 | 0 |
| 30 Apr 2023 | 2 | 0 | 8 | 0 |
| 7 May 2023 | 10 | 0 | 7 | 2 |
| 14 May 2023 | 6 | 2 | 6 | 4 |
| 21 May 2023 | 5 | 0 | 9 | 0 |
| 28 May 2023 | 4 | 2 | 5 | 0 |
| 4 Jun 2023 | 2 | 0 | 0 | 0 |
| 11 Jun 2023 | 2 | 3 | 5 | 0 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 182 |
|---|---|
| Oct 2023 | 172 |
| Nov 2023 | 237 |
| Dec 2023 | 203 |
| Jan 2024 | 305 |
| Feb 2024 | 345 |
| Apr 2024 | 391 |
| May 2024 | 403 |
| Jan 2025 | 181 |
| Feb 2025 | 208 |
| May 2025 | 235 |
| Jul 2025 | 180 |
| Aug 2025 | 162 |
| Sep 2023 | 4,800 |
|---|---|
| Oct 2023 | 4,800 |
| Nov 2023 | 4,800 |
| Dec 2023 | 4,800 |
| Jan 2024 | 4,800 |
| Feb 2024 | 4,800 |
| Mar 2024 | 5,400 |
| Apr 2024 | 5,400 |
| May 2024 | 5,400 |
| Jun 2024 | 5,400 |
| Jul 2024 | 5,400 |
Vertex Pharmaceuticals Incorporated other data
88.99%
+0.68%
of VRTX is owned by hedge funds
1.03K
+25
231.29M
+1.94M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 67500 |
| Apr 2024 | 0 | 240 |
| May 2024 | 0 | 34592 |
| Jun 2024 | 0 | 17273 |
| Jul 2024 | 0 | 34964 |
| Aug 2024 | 0 | 13297 |
| Oct 2024 | 0 | 999 |
| Nov 2024 | 0 | 18213 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ALTSHULER DAVID officer: EVP, Ch.. | Common Stock | 15 | $478.56 | $7,178 | ||
Sale | WAGNER CHARLES F JR officer: EVP & Ch.. | Common Stock | 3,000 | $518.27 | $1,554,810 | ||
Sale | WAGNER CHARLES F JR officer: EVP & Ch.. | Common Stock | 3,000 | $518.27 | $1,554,810 | ||
Sale | KEWALRAMANI RESHMA director, officer.. | Common Stock | 15,198 | $515 | $7,826,970 | ||
Sale | BILLER JONATHAN officer: EVP and .. | Common Stock | 999 | $461.66 | $461,198 | ||
Sale | BILLER JONATHAN officer: EVP and .. | Common Stock | 999 | $461.66 | $461,198 | ||
Sale | LEIDEN JEFFREY M director, officer.. | Common Stock | 3,784 | $499 | $1,888,216 | ||
Option | BHATIA SANGEETA N. director | Common Stock | 646 | $152.74 | $98,670 | ||
Sale | BHATIA SANGEETA N. director | Common Stock | 646 | $500 | $323,000 | ||
Option | BHATIA SANGEETA N. director | Stock Option (Right to Buy) | 646 | $152.74 | $98,670 |
| Patent |
|---|
Grant Utility: Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Filling date: 17 Aug 2020 Issue date: 27 Sep 2022 |
Grant Filling date: 27 Aug 2020 Issue date: 13 Sep 2022 |
Grant Filling date: 2 Aug 2018 Issue date: 6 Sep 2022 |
Grant Utility: Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders Filling date: 27 Jun 2017 Issue date: 30 Aug 2022 |
Application Filling date: 15 Sep 2021 Issue date: 18 Aug 2022 |
Grant Utility: Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Filling date: 12 Apr 2019 Issue date: 16 Aug 2022 |
Application Filling date: 15 Sep 2021 Issue date: 4 Aug 2022 |
Application Filling date: 11 Feb 2022 Issue date: 28 Jul 2022 |
Application Filling date: 3 Aug 2021 Issue date: 28 Jul 2022 |
Grant Filling date: 7 Jul 2020 Issue date: 19 Jul 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 5 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Reshma Kewalramani FASN, M.D. (1973) Chief Executive Officer, Pres & Director | $3,860,000 |
| Dr. Jeffrey Marc Leiden M.D., Ph.D. (1956) Executive Chairman | $3,140,000 |
Mr. Stuart A. Arbuckle B.Sc. (1966) Executive Vice President & Chief Operating Officer | $2,030,000 |
| Dr. David M. Altshuler (1965) Executive Vice President of Global Research & Chief Scientific Officer | $1,810,000 |
| Mr. Charles F. Wagner Jr. (1968) Executive Vice President & Chief Financial Officer | $1,710,000 |
What To Do With These Seven Stocks After They Plunged
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
CRISPR Therapeutics: Shares Are Soaring--This Could Be The Start Of Something Big
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
Crispr Therapeutics: Betting On A One-Shot Future
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
-
What's the price of Vertex Pharmaceuticals Incorporated stock today?
One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $390.5.
-
When is Vertex Pharmaceuticals Incorporated's next earnings date?
Unfortunately, Vertex Pharmaceuticals Incorporated's (VRTX) next earnings date is currently unknown.
-
Does Vertex Pharmaceuticals Incorporated pay dividends?
No, Vertex Pharmaceuticals Incorporated does not pay dividends.
-
How much money does Vertex Pharmaceuticals Incorporated make?
Vertex Pharmaceuticals Incorporated has a market capitalization of 102.10B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.51% to 9.87B US dollars. Vertex Pharmaceuticals Incorporated earned 3.62B US dollars in net income (profit) last year or $3.25 on an earnings per share basis.
-
What is Vertex Pharmaceuticals Incorporated's stock symbol?
Vertex Pharmaceuticals Incorporated is traded on the NASDAQ under the ticker symbol "VRTX".
-
What is Vertex Pharmaceuticals Incorporated's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vertex Pharmaceuticals Incorporated?
Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vertex Pharmaceuticals Incorporated's key executives?
Vertex Pharmaceuticals Incorporated's management team includes the following people:
- Dr. Reshma Kewalramani FASN, M.D. Chief Executive Officer, Pres & Director(age: 52, pay: $3,860,000)
- Dr. Jeffrey Marc Leiden M.D., Ph.D. Executive Chairman(age: 69, pay: $3,140,000)
- Mr. Stuart A. Arbuckle B.Sc. Executive Vice President & Chief Operating Officer(age: 59, pay: $2,030,000)
- Dr. David M. Altshuler Executive Vice President of Global Research & Chief Scientific Officer(age: 60, pay: $1,810,000)
- Mr. Charles F. Wagner Jr. Executive Vice President & Chief Financial Officer(age: 57, pay: $1,710,000)
-
How many employees does Vertex Pharmaceuticals Incorporated have?
As Jul 2024, Vertex Pharmaceuticals Incorporated employs 5,400 workers.
-
When Vertex Pharmaceuticals Incorporated went public?
Vertex Pharmaceuticals Incorporated is publicly traded company for more then 34 years since IPO on 24 Jul 1991.
-
What is Vertex Pharmaceuticals Incorporated's official website?
The official website for Vertex Pharmaceuticals Incorporated is vrtx.com.
-
Where are Vertex Pharmaceuticals Incorporated's headquarters?
Vertex Pharmaceuticals Incorporated is headquartered at 50 Northern Avenue, Boston, MA.
-
How can i contact Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated's mailing address is 50 Northern Avenue, Boston, MA and company can be reached via phone at +61 73416100.
-
What is Vertex Pharmaceuticals Incorporated stock forecast & price target?
Based on 7 Wall Street analysts` predicted price targets for Vertex Pharmaceuticals Incorporated in the last 12 months, the avarage price target is $493.78. The average price target represents a 26.44% change from the last price of $390.5.
Vertex Pharmaceuticals Incorporated company profile:
Vertex Pharmaceuticals Incorporated
vrtx.comExchange:
NASDAQ
Full time employees:
5,400
Industry:
Biotechnology
Sector:
Healthcare
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
50 Northern Avenue
Boston, MA 02210
Boston, MA 02210
CIK: 0000875320
ISIN: US92532F1003
CUSIP: 92532F100
